ClinicalTrials.gg
CompletedNCT00647400Updated Apr 8, 2011Results posted

Adalimumab in Adult Japanese Subjects With Psoriasis

A Phase 2/3 interventional study of adalimumab and adalimumab in Psoriasis, sponsored by Abbott. Completed at 64 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-04-08.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
26th of 48
147 · median 148
Started
2006
the only one that year
Phase 2/3
Only one
of the 48
Registered
10th of 48
by date
Lead sponsor
11 of 48
Abbott

Among the 48 studies testing adalimumab in Psoriasis, this one is the 26th largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis

Read the detailed description

This was a continuation trial of adalimumab in participants with moderate to severe chronic plaque psoriasis who had completed Study M04-688 (NCT00338754), a 24-week, double-blind, placebo-controlled study. This study was an open-label extension study that continued until the approval of adalimumab for the treatment of psoriasis in Japan.

During Study M04-688 (NCT00338754), participants received 24 weeks of treatment with adalimumab 40 mg every other week (eow) with or without a loading dose, adalimumab 80 mg eow, or placebo.

At the start of this study, participants who had received adalimumab 40 mg eow or adalimumab 80 mg eow in Study M04-688 (NCT00338754) continued on the same treatment regimen. Participants who had received placebo during Study M04-688 (NCT00338754) were re-randomized at the start of this study to receive adalimumab 40 mg eow or adalimumab 80 mg eow.

Participants in the adalimumab 40 mg eow treatment group who failed to achieve a PASI50 response (>= 50% reduction in the Psoriasis Area and Severity Index score from Baseline of Study M04-688 [NCT00338754]) at or anytime after Week 12 of this study were given the option to increase their dose to adalimumab 80 mg eow. Once the dose was escalated, there was no option to de-escalate dosing back to 40 mg eow. Participants who failed to achieve PASI50 responses while receiving adalimumab 80 mg eow may have been discontinued from the study after evaluating the risk/benefit of further treatment with adalimumab.

At Week 28 of this study, it was mandatory for all participants who started the study in the adalimumab 80 mg eow treatment group (i.e., not including the dose escalators described above) to reduce their dose to adalimumab 40 mg eow, regardless of their response status. Following this mandatory dose reduction, if these participants failed to achieve or maintain PASI50 response, they were permitted to escalate their dose to adalimumab 80 mg eow. There was no option to de-escalate dosing back to 40 mg eow following dose escalation.

Data in this clinical trial results disclosure are analyzed as observed according to treatment received at the start of this study (i.e., adalimumab 40 mg eow or adalimumab 80 mg eow) regardless of subsequent dose escalation. Data are summarized according to participants' cumulative exposure to adalimumab in Study M04-688 (NCT00338754) and this study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed Study M04-688 (NCT00338754)

Exclusion criteria

Exclusion Criteria:

  • Participant is considered by the investigator, for any reason, to be an unsuitable candidate for the study
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg every other week

    Biological: adalimumab

  • Experimental
    Adalimumab 80 mg every other week

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Adalimumab 40 mg every other week, subcutaneous

    Also known as: ABT-D2E7, Humira

  • Biologicaladalimumab

    Adalimumab 80 mg every other week, subcutaneous

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)

    PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

    Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab

Secondary outcomes

  1. Number of Participants With a 75% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI75 Response)

    PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

    Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab

  2. Number of Participants With a 90% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI90 Response)

    PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

    Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab

07

Results

Posted Jan 11, 2010

Participant flow

Japanese participants with chronic plaque psoriasis who completed the blinded, placebo-controlled Study M04-688 (NCT00338754; 24-week duration) enrolled in the extension study, M04-702, an open-label study until adalimumab received approval for treatment of psoriasis in Japan.

Participant flow — Overall Study
MilestoneAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
Started8958
Completed6745
Not completed2213

Outcome measures

PrimaryNumber of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)

PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

Time frame:
Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Reported as:
Number · Participants
Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)
ParticipantsAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow])7854
24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow])8055
36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow])7952
52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow])8051
76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow])7652
100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow])7549
160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow])7147
208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow])2914
SecondaryNumber of Participants With a 75% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI75 Response)

PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

Time frame:
Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Reported as:
Number · Participants
Number of Participants With a 75% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI75 Response)
ParticipantsAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow])5445
24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow])6950
36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow])6551
52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow])6748
76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow])7047
100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow])6643
160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow])6941
208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow])2713
SecondaryNumber of Participants With a 90% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI90 Response)

PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).

Time frame:
Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Reported as:
Number · Participants
Number of Participants With a 90% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI90 Response)
ParticipantsAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow])3129
24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow])5039
36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow])5444
52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow])5442
76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow])5538
100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow])5535
160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow])5733
208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow])2312

Adverse events

Collected over Adverse events are reported starting from the first dose of adalimumab (in Study M04-688 [NCT00338754] or in Study M04-702) up to 70 days after the last dose of adalimumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg Every Other Week—19/89 (21.3%)88/89 (98.9%)
Adalimumab 80 mg Every Other Week—11/58 (19%)58/58 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
Angina pectorisCardiac disorders1/892/58
Acute myocardial infarctionCardiac disorders0/891/58
Inguinal herniaGastrointestinal disorders0/891/58
Viral infectionInfections and infestations0/891/58
Rib fractureInjury, poisoning and procedural complications0/891/58
Thermal burnInjury, poisoning and procedural complications0/891/58
AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/891/58
Cerebral infarctionNervous system disorders1/891/58
EncephalitisNervous system disorders0/891/58
AsthmaRespiratory, thoracic and mediastinal disorders1/891/58
Most frequent other events
Showing 10 of 107
Most frequent other events
EventAdalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other Week
NasopharyngitisInfections and infestations67/8945/58
Blood triglycerides increasedInvestigations22/8917/58
Blood creatine phosphokinase increasedInvestigations21/8915/58
DiarrhoeaGastrointestinal disorders20/8914/58
FolliculitisInfections and infestations21/8914/58
Alanine aminotransferase increasedInvestigations21/899/58
Antinuclear antibody increasedInvestigations21/898/58
Back painMusculoskeletal and connective tissue disorders19/8910/58
HeadacheNervous system disorders19/898/58
Dental cariesInfections and infestations18/896/58

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other WeekTotal
<=18 years000
Between 18 and 65 years8056136
>=65 years9211
Age Continuous
Age Continuous(years)Adalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other WeekTotal
Mean45.1 ± 13.3942.9 ± 11.8844.2 ± 12.82
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other WeekTotal
Female131023
Male7648124
Region of Enrollment
Region of Enrollment(participants)Adalimumab 40 mg Every Other WeekAdalimumab 80 mg Every Other WeekTotal
Japan8958147
08

Study locations

64 sites
  • Site Ref # / Investigator 5491
    Bunkyo-ku, Japan
  • Site Ref # / Investigator 5429
    Chiyoda-ku, Japan
  • Site Ref # / Investigator 5464
    Fukuoka, Japan
  • Site Ref # / Investigator 5477
    Fukuoka, Japan
  • Site Ref # / Investigator 5492
    Fukuoka, Japan
  • Site Ref # / Investigator 5504
    Fukuoka, Japan
  • Site Ref # / Investigator 5400
    Fukushima-city, Japan
  • Site Ref # / Investigator 5406
    Fukushima-city, Japan
  • Site Ref # / Investigator 5407
    Fukushima-city, Japan
  • Site Ref # / Investigator 5437
    Fukushima-city, Japan
  • Site Ref # / Investigator 5401
    Gifu, Japan
  • Site Ref # / Investigator 5434
    Gifu, Japan
  • Site Ref # / Investigator 5408
    Hamamatsu, Japan
  • Site Ref # / Investigator 5495
    Hiroshima-city, Japan
  • Site Ref # / Investigator 5391
    Hokkaido, Japan
  • Site Ref # / Investigator 5402
    Ishikawa, Japan
  • Site Ref # / Investigator 5431
    Itabashi-ku, Japan
  • Site Ref # / Investigator 5395
    Iwate, Japan
  • Site Ref # / Investigator 5462
    Kagoshima, Japan
  • Site Ref # / Investigator 5476
    Kagoshima, Japan
  • Site Ref # / Investigator 5435
    Kanagawa, Japan
  • Site Ref # / Investigator 5432
    Kawachi-gun, Japan
  • Site Ref # / Investigator 5440
    Kawasaki-city, Japan
  • Site Ref # / Investigator 5499
    Kyoto, Japan
  • Site Ref # / Investigator 5503
    Kyoto, Japan
  • Site Ref # / Investigator 5411
    Minato-ku, Japan
  • Site Ref # / Investigator 5404
    Mitaka, Japan
  • Site Ref # / Investigator 5417
    Miyagi, Japan
  • Site Ref # / Investigator 5463
    Nagasaki, Japan
  • Site Ref # / Investigator 5427
    Nagoya-city, Japan
  • Site Ref # / Investigator 5465
    Nankoku-city, Japan
  • Site Ref # / Investigator 5493
    Nankoku-city, Japan
  • Site Ref # / Investigator 5482
    Nishinomiya-city, Japan
  • Site Ref # / Investigator 5496
    Okayama-city, Japan
  • Site Ref # / Investigator 5441
    Osaka-city, Japan
  • Site Ref # / Investigator 5467
    Osaka-city, Japan
  • Site Ref # / Investigator 5480
    Osaka-city, Japan
  • Site Ref # / Investigator 5483
    Osaka-city, Japan
  • Site Ref # / Investigator 5498
    Osaka-city, Japan
  • Site Ref # / Investigator 5388
    Sapporo, Japan
  • Site Ref # / Investigator 5396
    Sapporo, Japan
  • Site Ref # / Investigator 5399
    Sapporo, Japan
  • Site Ref # / Investigator 5414
    Shinjuku-ku, Japan
  • Site Ref # / Investigator 5433
    Shizuoka, Japan
  • Site Ref # / Investigator 5466
    Suita-city, Japan
  • Site Ref # / Investigator 5497
    Suita-city, Japan
  • Site Ref # / Investigator 5505
    Suita-city, Japan
  • Site Ref # / Investigator 5481
    Tokushima, Japan
  • Site Ref # / Investigator 5506
    Tokushima, Japan
  • Site Ref # / Investigator 6918
    Tokushima, Japan
  • Site Ref # / Investigator 5405
    Tokyo, Japan
  • Site Ref # / Investigator 5409
    Tokyo, Japan
  • Site Ref # / Investigator 5410
    Tokyo, Japan
  • Site Ref # / Investigator 5412
    Tokyo, Japan
  • Site Ref # / Investigator 5413
    Tokyo, Japan
  • Site Ref # / Investigator 5430
    Tokyo, Japan
  • Site Ref # / Investigator 6553
    Tokyo, Japan
  • Site Ref # / Investigator 5468
    Tsu, Japan
  • Site Ref # / Investigator 5475
    Ube-city, Japan
  • Site Ref # / Investigator 5415
    Urayasu, Japan
  • Site Ref # / Investigator 5438
    Urayasu, Japan
  • Site Ref # / Investigator 5416
    Yamagata, Japan
  • Site Ref # / Investigator 5403
    Yokohama, Japan
  • Site Ref # / Investigator 5428
    Yokohama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Sep 2007 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Mar 31, 2008
Start
Apr 2006
Primary completionActual
Sep 2007
CompletionActual
Apr 2010
Results first posted
Jan 11, 2010
Last update
Apr 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00647400
Lead sponsor
Abbott
Collaborators
Abbott Japan Co.,Ltd, Eisai Co., Ltd.
First posted
Mar 31, 2008
Start date
Apr 2006
Primary completion
Sep 2007
Completion
Apr 2010
Results posted
Jan 11, 2010
Last update
Apr 8, 2011

Study contacts

Kazuko Kobayashi
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion